Serum myeloperoxidase is independent of the risk factors of atherosclerosis

Coronary Artery Disease

Volumn 23, Issue 4, 2012, Pages 251-258

  Salonen, Iiris ^c   Huttunen, Kati ^a,b   Hirvonen, Maija Riitta ^a   Dufva, Juhani ^e   Groundstroem, Kaj ^d   Dufva, Hilkka ^e   Pekkanen, Juha ^b   Salonen, Raimo O ^b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c Kymenlaakso Hospital Services   (Finland)

^d KYMENLAAKSO CENTRAL HOSPITAL   (Finland)

^e Faculty of Medicine   (Finland)

Author keywords

atherosclerosis; atherosclerotic plaque; inflammation; ischemic heart disease; myeloperoxidase; risk factor

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; MYELOPEROXIDASE; TROPONIN I;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; FEMALE; GLUCOSE METABOLISM; HUMAN; ISCHEMIC HEART DISEASE; LEUKOCYTE; LIPID METABOLISM; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; C-REACTIVE PROTEIN; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; INFLAMMATION; LEUKOCYTE COUNT; LIPIDS; MALE; MIDDLE AGED; MYOCARDIAL ISCHEMIA; PEROXIDASE; RISK FACTORS;

EID: 84860842051     PISSN: 09546928     EISSN: 14735830     Source Type: Journal    
DOI: 10.1097/MCA.0b013e328353a676     Document Type: Article

References (29)

1. Takahiko N, Ueda M, Haze K, van der Wal AC, van der Loos CM, Itoh A, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation 2002; 106:2894-2900. (Pubitemid 35424738)
2. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, et al. On the behalf of the Committee on standardization of markers of cardiac damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005; 51:810-824. (Pubitemid 40577917)
3. Sugiyama S, Okada Y, Sukhova GK, Virmani R, Heinecke JW, Libby P. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol 2001; 158:879-891. (Pubitemid 32221781)
4. Schindhelm RK, van der Zwan LP, Teerlink T, Scheffer PG. Myeloperoxidase: a useful biomarker for cardiovascular disease risk stratification? Clin Chem 2009; 55:1462-1470.
5. Tang WH, Wu Y, Nicholls SJ, Hazen SL. Plasma myeloperoxidase predicts incident cardiovascular risks in stable patients undergoing medical management for coronary artery disease. Clin Chem 2011; 57:33-39.
6. Zhang R, Brennan ML, Fu X, Aviles RJ, Pearse GL, Penn MS, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA 2001; 286:2136-2142. (Pubitemid 34041599)
7. Baldus S, Heeschen C, Meinertz T, Zeiher AM, Eiserich JP, Munzel T, et al. On behalf of the CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation 2003; 108:1440-1445. (Pubitemid 37176448)
8. Brennan ML, Penn MS, Van Lente F, Nambi V, Shishehbor MH, Aviles RJ, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349:1595-1604. (Pubitemid 37288567)
9. Cavusoglu E, Ruwende C, Eng C, Chopra V, Yanamadala S, Clark LT, et al. Usefulness of baseline plasma myeloperoxidase levels as an independent predictor of myocardial infarction at two years in patients presenting with acute coronary syndrome. Am J Cardiol 2007; 99:1364-1368. (Pubitemid 46686633)
10. Goldhammer E, Ben Moshe Y, Lubovich A, Rivlin Y, Maor I, Zeina R, et al. Serum endothelin-1, MMP-9, and myeloperoxidase and coronary artery morphology as detected by multi-slice CT angiography in intermediate and high risk asymptomatic subjects. Open Biomarkers J 2010; 3:7-12.
11. Stefanescu A, Braun S, Ndrepepa G, Koppara T, Pavaci H, Mehilli J, et al. Prognostic value of plasma myeloperoxidase concentration in patients with stable coronary artery disease. Am Heart J 2008; 155:356-360.
12. Meuwese MC, Stroes ES, Hazen SL, van Miert JN, Kuivenhoven JA, Schaub RG, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol 2007; 50:159-165. (Pubitemid 47002189)
13. Ridker PM, Rifai N. C-reactive protein and cardiovascular disease. St-Laurent, Canada: MediEdition Inc.; 2006.
14. Rückerl R, Greven S, Ljungman P, Aalto P, Antoniades C, Bellander T, et al. For the AIRGENE Study. Air pollution and inflammation (IL-6, CRP, fibrinogen) in myocardial infarction survivors. Environ Health Perspect 2007; 115:1072-1080. (Pubitemid 47317075)
15. Prineas R, Crow R, Blackburn H. The Minnesota Code manual of electrocardiographic findings. Littleton, MA: John Wright-PSG Inc.; 1982.
16. Pocock SJ. Clinical trials. A practical approach. New York: Wiley; 1983.
17. Grimaldi E, Scopacasa F. Evaluation of the Abbott CELL-DYN 4000 hematology analyzer. Am J Clin Pathol 2000; 113:497-505. (Pubitemid 30217357)
18. Singh U, Devaraj S, Jialal I. C-reactive protein stimulates myeloperoxidase release from polymorphonuclear cells and monocytes: implications for acute coronary syndromes. Clin Chem 2009; 55:361-364.
19. Quist-Paulsen P. Statins and inflammation: an update. Curr Opin Cardiol 2010; 25:399-405.
20. Andreou I, Tousoulis D, Miliou A, Tentolouris C, Zisimos K, Gounari P, et al. Effects of rosuvastatin on myeloperoxidase levels in patients with chronic heart failure: a randomized placebo-controlled study. Atherosclerosis 2010; 210:194-198.
21. Devaraj S, Siegel D, Jialal I. Statin therapy in metabolic syndrome and hypertension post-JUPITER: what is the value of CRP? Curr Atheroscler Rep 2011; 13:31-42.
22. Videm V, Olsen GD. No relationship between neutrophil granulocyte activation and the myeloperoxidase gene-129 G > A and-463 G < A promoter polymorphisms: implications for investigations of cardiovascular disease. Coron Artery Dis 2009; 20:446-452.
23. Jornayvaz FR, Brulhart-Meynet MC, James RW. Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis 2009; 19:613-619.
24. Moldoveanu E, Tanaseanu C, Tanaseanu S, Kosaka T, Manea G, Marta DS, et al. Plasma markers of endothelial dysfunction in type 2 diabetics. Eur J Intern Med 2006; 17:38-42. (Pubitemid 43003460)
25. Shih J, Datwyler SA, Hsu SC, Matias MS, Pacenti DP, Lueders C, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem 2008; 54:1076-1079. (Pubitemid 351793416)
26. Chan D, Ng L. Biomarkers in acute myocardial infarction. BMC Med 2010; 8:34.
27. Wu AHB. Novel biomarkers of cardiovascular disease: myeloperoxidase for acute and/or chronic heart failure? Clin Chem 2009; 55:12-14.
28. Fichtlscherer S, Heeschen C, Zeiher AM. Inflammatory markers and coronary artery disease. Curr Opin Pharmacol 2004; 4:124-131. (Pubitemid 38444046)
29. Koenig W, Khuseyinova N. Biomarkers of atherosclerotic plaque rupture. Arterioscler Thromb Vasc Biol 2007; 27:15-26.